Importantly, simvastatin, a mevalonate inhibitor widely used for treatment of cancer, significantly diminished the level of the E3 activity-limited isoform of RNF128, thus triggering degradation of mtp53 by the E3 activity-proficient RNF128 (Figure 1) [87]. The gene discussed is RNF128; the disease is cancer.